Neuling braucht hilfe ! - 500 Beiträge pro Seite

[GBSNEU]

Hallo Boersianer !?,

Wer kann mir Info^s geben ueber QQQQ.
Wurden zum Kauf empfohlen.

Danke, GBSNEU.

[Zweite Million]

Du bist mit QQQQ im falschen board, NASDAQ und/oder Biotech is the place


ST. PAUL, Minn., Jan. 18 /PRNewswire/ --
Quantech Ltd. (OTC Bulletin Board: QQQQ), today announced that it has made itsfinal minimum royalty payment on its license for its SPR technology. Theability of Quantech to maintain its exclusive worldwide rights to thetechnology is no longer subject to minimum payments, but royalties only uponthe sale of product.
"The minimum royalties have been a financial burden to Quantech during itsdevelopment stage," said Robert Case, chief executive officer of Quantech."This last minimum payment comes at a very important time as the company movestoward the introduction of a commercial product this year. Our rights to thetechnology are now further solidified and future royalty payments will be made
only as a direct result of product sales," Case explained.
Based in St. Paul, Minn., Quantech is completing development of its
Emergency Department (ED) FasTraQ(TM) Patient Treatment Information Platform.
The core of this platform is Quantech`s user-friendly and rapid diagnostic
system that uses its proprietary Surface Plasmon Resonance (SPR) technology.
The Quantech instrument will allow the ED staff to perform time-critical
diagnostic tests for multiple patients, simultaneously and directly from tubes
of whole blood. The platform will also allow the wireless delivery of test
results directly to the appropriate ED nurse and physician at bedside in less
than 15 minutes, without further ED staff intervention. Quantech`s instrument
is expected to include an initial menu of tests grouped in patient
diagnosis-related panels including cardiac enzymes (heart attack), pregnancy,
red and white blood cell counts, blood coagulation and kidney function.
Additional tests for liver functions, electrolytes, drugs of abuse,
therapeutic drugs and other STAT tests are also expected to be available on
the system. Quantech has received clearance from the U.S. Food and Drug
Administration to market its tests for the cardiac enzymes Myoglobin and CK-MB
and the pregnancy enzyme hCG.
"Safe Harbor" statement under the Private Securities Litigation Reform Act
of 1995: Any statements which are not historical facts contained in this
release are forward looking statements that involve risk and uncertainties,
including but not limited to those relating to product demand, pricing,
market acceptance, the effect of economic conditions, the validity and
enforceability of intellectual property rights, the outcome of government
regulatory proceedings, competitive products, risks in product and technology
development, the ability to complete transactions, and other risks identified
in the company`s Securities and Exchange Commission filings.
For more information contact Doug Ewing of BlueFire Partners,
612-371-0000, for Quantech Ltd., or Gregory G. Freitag, COO and CFO of
Quantech Ltd., 651-647-6370.